Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2005 / Cilt: 51 - Sayı: 3

Intravesical botulinum-A toxin injection in the treatment of neurogenic detrusor overactivity: A case report and literature review

Nörojenik aşırı aktif detrüsöz tedavisinde intravezikal botulinum-A toksin enjeksiyonu: Bir olgu sunumu ve literatürün gözden geçirilmesi

Pages
117–119
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Urodynamic examination which was done 4 months after the injection revealed that maximum cystometric bladder capacity increased from 108 to 250 ml and maximum detrusor pressure decreased from 63 to 35 cmH2O

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 45-year-old man applied to our department with the complaints of urinary and faecal incontinence and muscle weakness in the lower limbs.
📊
Key Findings & Data:He had progressive myelopathy caused by intracranial dural arteriovenous fistula with venous drainage into the spinal perimedullary veins.In the first urodynamic examination, maximum cystometric bladder capacity was 164 ml and maximum detrusor pressure was 50 cmH2O with detrusor-sphincter dyssinergia.
💡
Conclusion & Impact:Urodynamic examination which was done 4 months after the injection revealed that maximum cystometric bladder capacity increased from 108 to 250 ml and maximum detrusor pressure decreased from 63 to 35 cmH2O
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 45-year-old man applied to our department with the complaints of urinary and faecal incontinence and muscle weakness in the lower limbs. He had progressive myelopathy caused by intracranial dural arteriovenous fistula with venous drainage into the spinal perimedullary veins.In the first urodynamic examination, maximum cystometric bladder capacity was 164 ml and maximum detrusor pressure was 50 cmH2O with detrusor-sphincter dyssinergia. Intermittent self-catheterization and oxybutynin chloride 10 mg daily was started. One year later, it was increased to 15 mg daily as it was ineffective to achieve continence. As the patient had a problem of dry mouth, it was changed to tolterodine 4 mg daily. The patient showed inadequate response to this treatment one year later. He still had detrusor overactivity and incontinence episodes between intermittent catheterisations. Botulinum-A toxin injection into the detrusor muscle of this patient was decided as the incontinence was resistant to anticholinergic therapy. A total of 300 units of botulinum-A toxin were injected with a custom made 6 Fr flexible injection needle at 30 detrusor muscle sites. Urodynamic examination which was done 4 months after the injection revealed that maximum cystometric bladder capacity increased from 108 to 250 ml and maximum detrusor pressure decreased from 63 to 35 cmH2O

Özet

45 yaşındaki erkek hasta, idrar-gaita inkontinansı ve alt ekstremitelerdeki kas güçsüzlüğü ile kliniğimize başvurdu. Hastada spinal perimedüller venlere drene olan dural arteriovenöz fistüle bağlı progresif myelopati saptandı. İlk ürodinamik incelemede maksimum sistometrik mesane kapasitesi 164 ml, maksimum detrüsör basıncı 50 cmH2O idi ve detrüsör-sfinkter dissinerjisi mevcuttu. Aralıklı kateterizasyon ile birlikte oksibutinin klorid 10 mg/gün dozunda başlandı. Bir yıl sonra, bu doz kontinensi sağlamada yetersiz olduğu için 15 mg/gün’e artırıldı. Ancak, hastanın ağız kuruluğu sorunu olduğu için, tolterodin 4 mg/gün’e değiştirildi. Hasta bir yıl sonra bu tedaviye yetersiz yanıt gösterdi. Kateterizasyonlar arasında inkontinans epizodları devam etmekteydi ve detrüsör aşırı aktivitesi vardı. İnkontinans antikolinerjik tedaviye direnç gösterdiği için, hastanın detrüsör kasına botulinum toksin-A uygulanmasına karar verildi. Detrüsör kasın, 30 bölgesine fleksibl 6 Fr enjeksiyon iğnesi ile toplam 300 ünite botulinum-A toksini enjekte edildi. Enjeksiyondan 4 ay sonra yapılan ürodinamik incelemede, maksimum sistometrik mesane kapasitesin 108 ml’den 250 ml’ye arttığı, maksimum detrüsör basıncının ise 63 cmH2O’dan 35 cmH2O’ya düştüğü saptandı.

🔖

Cite This Article

ÖZDEDELİ, S., AKKOÇ, Y., ÖZDEDELİ, K. (2022). Intravesical botulinum-A toxin injection in the treatment of neurogenic detrusor overactivity: A case report and literature review. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 51 - Sayı: 3, 117–119. https://ajindex.com/articles/629382

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve 1997;6(Suppl):S129-45
  2. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990;71(1):24-6
  3. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996;155(3):1023-9
  4. Jost WH, Naumann M. Botulinum toxin in neuro-urological disorders. Movement Disorders 2004;19(8)(Supp):S142-5
  5. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164:692-7
  6. Abrams P, Larsson G, Chapple C, Wein AJ. Factors involved in the success of antimuscarinic treatment. BJU Int 1999;83(Suppl 2):S42–7
  7. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81(6):801–10
  8. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynine and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10(5):283–9
  9. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997;50 (6A Suppl):S90–6 [Discussion 97–9]
  10. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41(6):588–95
  11. Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord 2004;42(5):267-72
  12. Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 1976;8(5):452–4
  13. Brindley GS, Polkey CE, Rushton DN. Sacral anterior root stimulators for bladder control in paraplegia. Paraplegia 1982;20(6):365-81
  14. Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord 1997;35(7):456-62
  15. Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO, Chancellor MB, Richard F, Denys P. Long-term results of augmentation cystoplasty in spinal cord injury patients. S